Facebook
Instagram
Linkedin
Youtube
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Search
BioStock
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Home
Search
stayble
-
search results
If you're not happy with the results, please do another search
Stayble’s CEO: “We are looking forward to new study results in...
12 January, 2024
Stayble’s new analyses of phase IIb study strengthen disc herniation project
18 December, 2023
Stayble Therapeutics shifts focus to phase Ib study in disc herniation
22 November, 2023
Stayble did not reach the primary endpoint in phase IIb
9 November, 2023
Stayble Therapeutics presents phase IIb data within one month
3 November, 2023
Stayble reports last patient last visit in the phase IIb study
14 September, 2023
Stayble enrols the first patient in herniated disc study
4 September, 2023
Progress for Stayble Therapeutics in the second quarter
25 August, 2023
Stayble’s phase IIb study nears the finishing line
24 July, 2023
Stayble Therapeutics looks to its most important year so far
19 June, 2023
Newly appointed CMO sees potential in Stayble Therapeutics
27 April, 2023
Stayble presents additional positive interim data
18 April, 2023
Stayble adds disc herniation to the pipeline – study approved
7 March, 2023
Stayble is done with the 6-month follow-up
15 February, 2023
Stayble approaches study results and other milestones
27 January, 2023
Great interest at conferences for Stayble’s treatment
15 December, 2022
NLSDays: Stayble steps up partnering activities
4 October, 2022
Stayble reaches important milestone – completed patient recruitment
5 September, 2022
Stayble sums up and looks ahead
24 August, 2022
Stayble’s pathway to phase III and market
18 July, 2022
10 advantages of Stayble’s treatment
29 June, 2022
Watch day 2 of the BioStock Life Science Spring Summit
9 June, 2022
The BioStock Life Science Spring Summit starts now
8 June, 2022
KOL sees benefits with Stayble Therapeutics’ treatment
24 May, 2022
Stayble Therapeutics reaches patient recruitment milestone
3 May, 2022
The Ukraine crisis – an ethical dilemma for the life science...
29 March, 2022
BioStock Life Science Spring Summit, June 8-9, 2022
26 March, 2022
Stayble Therapeutics is addressing the opioid crisis
14 February, 2022
Stayble Therapeutics strengthened in 2021
15 December, 2021
Stayble Therapeutics’ CEO comments on positive interim results
10 November, 2021
Competitive landscape opens opportunities for Stayble Therapeutics
27 September, 2021
Stayble Therapeutics CEO sums up Q2 and looks ahead
23 August, 2021
Stayble Therapeutics prepares for partnership
14 July, 2021
Stayble Therapeutics – treating the underlying cause of back pain
3 July, 2021
Stayble Therapeutics’ studies published in leading journal
3 July, 2021
Stayble Therapeutics has initiated the phase IIb study in Spain
3 July, 2021
Staybe Therapeutics sees optimism amongst study clinics
2 July, 2021
Stayble Therapeutics gives update on phase IIb study
1 July, 2021
Stayble Therapeutics recruits VP CMC and Regulatory Affairs
1 July, 2021
Stayble Therapeutics elects new Chairman of the Board
3 June, 2021
Innovation in focus at BioStock Life Science Spring Summit 2021
25 May, 2021
Stayble Therapeutics’ SAB strengthened with two top names
26 January, 2021
Watch company presentations & panels from the BioStock Life Science Summit...
29 November, 2020
Strong line-up at the BioStock Life Science Summit 2020
16 November, 2020